MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

440.20 -51.29 (-10.44%)
Streaming Delayed Price Updated: 3:06 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Reports Q4 2025 Revenue Beat and Significant EPS Miss ↗
Via Chartmill
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗
The stock has had quite the run following Rezdiffra's 2024 approval by the FDA. 
Via The Motley Fool
News headline image
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗
There is a key difference between these two biotechs. 
Via The Motley Fool
Topics Bankruptcy
News headline image
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗
The pharmaceutical leader looks poised to stop the bleeding. 
Via The Motley Fool
News headline image
2 Predictions for Novo Nordisk in 2026 ↗
The company's worst days might be behind it. 
Via The Motley Fool
News headline image
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗
They haven't peaked yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗
Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures. 
Via Stocktwits
News headline image
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps. 
Via Benzinga
News headline image
Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge ↗
Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake. 
Via Chartmill
News headline image
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts ↗
In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives. 
Via Benzinga
News headline image
MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template ↗
Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating. 
Via Chartmill
News headline image
MarketBeat Week in Review – 09/08 - 09/12 ↗
Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in 
Via MarketBeat
Topics Economy
News headline image
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts ↗
 
Via Benzinga
News headline image
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals ↗
Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons. 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story